---
title: "Astromech’s $20M at a Reported $3.8B: Biology-as-Weather Models"
description: "Bob Nelsen led Astromech’s $20M round — Colossal spinout claiming a $3.8B valuation on ~$60M total raised to forecast evolutionary change. The valuation is the story; commercial pilots are next."
date: 2026-08-20T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "biotech", "artificial-intelligence"]
source: https://venturecapitaltracker.com/2026-astromech-20m-bob-nelsen-biology-prediction
---

# Astromech’s $20M at a Reported $3.8B: Biology-as-Weather Models

> Bob Nelsen led Astromech’s $20M round — Colossal spinout claiming a $3.8B valuation on ~$60M total raised to forecast evolutionary change. The valuation is the story; commercial pilots are next.

**Astromech**, a **Colossal Biosciences** spinout from **Ben Lamm** and **George Church**, raised **$20 million** led by **Bob Nelsen**, bringing total capital to about **$60 million** and a **reported $3.8 billion** valuation (SiliconANGLE, **August 20, 2026**). Participants named: **Peak 6**, **NeoGenesis Capital**, **Builders VC**, **CAZ Investments**.

**Spine / anomaly:** **~$60M** raised → **$3.8B** mark is a **valuation event**, not a commercial scale story. Diligence starts there.

## Key facts

| Field | Detail |
| --- | --- |
| Company | Astromech (Colossal spinout; predictive biology models) |
| Round | **$20M** |
| Lead | Bob Nelsen (personally; ARCH co-founder) |
| Valuation (reported) | **$3.8B** |
| Total raised (reported) | **~$60M** |
| Thesis | Forecast evolutionary / biological trajectories (“weather for biology”) |
| Near-term focus | Longevity gene mapping across species; biosecurity/health pilots |

## Who would use the product — and for what job

**Intended users:** longevity researchers, biosecurity teams, and eventually drug/health partners who need **hypothesis generation** across species and deep time — not another protein-only foundation model.

**Job:** combine genomic + evolutionary + functional data to anticipate disease progression, resistance, and vulnerability — Church emphasizes **ancestral regulatory states**, not just ancestral proteins.

## Why now

- Foundation-model capital is spilling into biology with extreme marks.
- Colossal’s public de-extinction brand creates distribution for spinout narratives.
- Longevity and biosecurity budgets are searching for differentiated datasets.

## Why Nelsen — portfolio fit

Nelsen’s biotech track record is the signal: a specialist writing conviction into a **platform biology** bet. Founders likely wanted a **biotech brand lead** who underwrites decade-scale science risk — not a general AI fund chasing LLM comps.

*Do not invent `/fund/arch-venture-partners` as the lead entity — SiliconANGLE attributes the lead to Bob Nelsen personally. Builders VC / others are not linked as `/fund/` pages here.*

## Competitive map

| Player | Difference |
| --- | --- |
| Protein / molecule foundation model cos (e.g. [Chai Discovery](/2026-chai-discovery-400m-series-c-index-sequoia)) | Different scientific object |
| Classical bioinformatics vendors | Weaker evolutionary deep-time framing |
| Colossal itself | Parent de-extinction ops vs predictive spinout IP |

## What is not proven

- Any revenue, contracted pilots, or pharma LOIs in the cited piece.
- Whether $3.8B is primary round pricing vs secondary/mark-to-market storytelling.
- Predictive accuracy outside curated longevity gene maps (46 genes cited as mapped).

## Practical takeaway

- **Founders:** If your mark is the headline, expect every diligence call to ask **what $3.8B buys in validated forecasts**.
- **Investors:** Separate **science optionality** from software SaaS multiples.
- **Operators:** Watch announced pilot partners — that is the next real data point.

### Sources

1. SiliconANGLE (Aug 20, 2026): https://siliconangle.com/2026/08/20/astromech-raises-20m-to-build-a-biological-operating-system-that-can-forecast-evolutionary-change/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.